Breast Cancer

The evolution of the treatment for hormone receptor-positive breast cancer was a hot topic for this year's Miami Breast Cancer Conference. Debu Tripathy, CURE's editor-in-chief and breast oncologist, reports from the meeting.

The management of patients with hormone receptor (HR)-positive breast cancer continues to evolve, with phase 3 studies shedding light on the length of adjuvant anti-estrogen therapy, a novel treatment gaining approval, and new trials exploring combination strategies.

Worrying and cancer go hand-in-hand. It's possible to take a step back from excessive worrying and give yourself a break.

The addition of Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel as a first-line therapy for metastatic HER2-positive breast cancer improved overall survival (OS) by nearly 16 months, according to findings from the phase 3 CLEOPATRA study.

Talk with almost any cancer survivor, and he or she is likely to bring up the topic of "chemobrain," that fuzzy, murky state that patients blame for impaired memory. A review of the research shows how we're focusing on the problem.

Throughout her treatment for breast cancer, TV personality Joan Lunden has advocated for patients like herself—while drawing strength from their support.

While science sometimes moves forward in quantum leaps, it more often advances in small steps, and this year's San Antonio Breast Cancer Symposium demonstrated both sides of that coin.

I went into dating after cancer with one goal, a decent date, and I got far more than I ever dreamed.

It's isolating to have cancer. Making a connection with someone who understands makes all the difference.

Anees B. Chagpar, director of the Breast Center at Smilow Cancer Hospital at Yale-New Haven Hospital in Connecticut, discusses why certain patients should receive genetic counseling and testing for breast cancer.

There's a list of things we're supposed to do as good patients. And then, there's the reality of living with cancer and doing the best we can.

Women diagnosed with early-stage breast cancer have a variety of decisions to make regarding treatment, but it's important for patients to realize all of their options when making those medical decisions.

The anticipated approval of Ibrance (palbociclib) came two months ahead of expectations, as the FDA granted an accelerated approval to the drug as a frontline treatment for women with ER-positive, HER2-negative metastatic breast cancer.

A new study has found that while the breast cancer prevention drug tamoxifen's benefits outweigh its risks, the drug isn't right for all women.

Every day, breast cancer researcher Edith Perez sets her mind on finding better treatments for the disease and conducting research aimed at improving patients' lives.

Journalist Joan Lunden shares her experience with breast cancer, side effects and working through treatment.

The emotional fallout of cancer takes a heavy toll. Experiencing your feelings in your own way, at your own pace, can be a challenge.

Two recent studies outline the importance of nutrition in preventing obesity-related cancers, as well as the potential benefits of a nutrition education intervention in preventing breast cancer recurrence.

Roy Firestone interviews longtime journalist, author and television host Joan Lunden on her recent breast cancer diagnosis and treatment.

Those of us living with metastatic cancer ride a see-saw between hope and acceptance.

Beth Overmoyer, a breast oncologist at Dana-Farber Cancer Institute, speaks on the results of the SOFT trial and its potential impact on young women with hormone receptor-positive breast cancer.

Women with hormone receptor-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant Aromasin, according to results from the phase 3 SOFT trial.

It's taken me a while to accept that it's OK to not be OK. Sometimes the only way to keep moving forward is to stop and have a pity party first.

The Food and Drug Administration's calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.

Results of a phase 2 study showed that women with small, stage 1 HER2-positive breast cancer who received a combination of lower-intensity chemotherapy and Herceptin following surgery were highly unlikely to have a recurrence.

When was your last truly remarkable New Year's Eve?

The mental challenges of having stage 4 breast cancer are just as overwhelming as the physical ones.

The mental noise that comes with cancer is deafening. Taking cancer time-outs can quiet your anxiety.

Two HER2-targeting regimens anchored by Kadcyla (T-DM1) failed to outperform the standard strategy of Herceptin plus chemotherapy in women newly diagnosed with advanced HER2-positive breast cancer.

The addition of Avastin (bevacizumab) to standard neoadjuvant chemotherapy significantly improved pathologic complete response rates in women with basal-like breast cancer compared with non-basal-like subtypes.